glp1 retatrutide Doctor Reveals The BEST GLP-1 For 2026 (Retatrutide vs Tirzepatide) Retatrutide 10mg Triple Agonist |

Ready to get the most out of your weight loss plan

Emerging data in clinical and preclinical studies suggests the adverse and efficacious effects of these pharmacotherapies can be dissociated, and that GIPR agonism improves the GI AE profile of GLP-1R and dual incretin receptor agonists

This shift can cause the body to store more fat around the abdomen instead of the hips and thighs

In extreme cases, people claim theyve lost teeth or had them crack unexpectedly

Choose Retatrutide If: Maximum weight loss is the primary goal Previous GLP-1 agonists produced significant nausea (GIP component may help) No specific liver health concerns requiring treatment Tolerance for slightly higher GI side effects during titration Response to dual agonists (like tirzepatide) has been positive Choose Survodutide If: Liver health concerns exist (fatty liver, MASH, elevated liver enzymes) Moderate weight loss goals rather than maximum efficacy priority Interest in potential cardiovascular outcome benefits (CVOT data pending) Preference for a compound with FDA Breakthrough Therapy designation Plans to potentially transition to approved medication once available For most people focused primarily on weight loss, Retatrutide presents the stronger option based on available data

Improved postprandial glucose metabolism in type 2 diabetes by the dual glucagon-like peptide-1/glucagon receptor agonist SAR425899 in comparison with liraglutide